26 September 2025
Plan-Les-Ouates & Zurich (CH) – Antwerp (BE)
Spineart (www.spineart.com), a global medtech innovator in advanced spine surgery solutions, today announces a CHF 25 million capital increase backed by its long-standing investors Gimv and EGS Beteiligungen (EGSB). This new funding will fuel Spineart’s next phase of profitable growth, enabling the company to advance its innovation pipeline and strengthen its global footprint in delivering better outcomes for spine surgery patients.
Spineart’s profitable growth strategy is anchored in a comprehensive portfolio of cutting-edge technologies designed to make spine surgery safer, more efficient and more effective. With a strong focus on clinical outcomes, the company is expanding across Europe and the United States with ongoing regulatory submissions to the U.S. FDA for its BAGUERA® C cervical disc prosthesis. Strategic partnerships and investments in digital navigation and robotics are also enhancing Spineart’s innovation capabilities, adding a transformative dimension to its future growth.
Spineart currently employs over 360 professionals worldwide and is projected to reach revenues of approximately EUR 140 million in 2025, reflecting five consecutive years of growth at an average annual rate of +16%. With a recently opened modern production facility in Reignier, France, the company is well-positioned to meet the rising global demand for its advanced spine surgery solutions.
“This investment represents a major milestone in Spineart’s profitable growth journey,” said Jerome Trividic, CEO of Spineart. “Over the past years, we’ve made targeted strategic investments in product innovation, robotics, regulatory expansion in Europe and the United States and manufacturing, that are now coming to fruition. With the continued support of Gimv and EGSB, we are well-positioned to scale globally, deliver innovative, differentiated technologies and reinforce our commitment to surgical excellence and improved patient outcomes.”
“Our sustained commitment to Spineart reflects our strong belief in the company’s innovation capabilities in the field of spine surgery and its international growth potential,” said Bart Diels and Gautier Lefebvre, respectively Managing Partner and Partner Healthcare of Gimv. “This investment fits perfectly with the ambition of our Healthcare platform to support pioneering companies shaping the future of healthcare and demonstrates our ability to successfully do it on the long run. This additional investment underlines Gimv’s accelerated growth ambitions. The total cumulative investment in the company makes it one of Gimv’s five largest investments.”
“As an investor in Spineart since 2020, we are very pleased with its strong development and remain fully committed to supporting this outstanding company,” said Dominik Sauter, former Managing Director and current Senior Advisor, and Christian Pfab, Member of the Executive Committee of EGSB. “Our additional investment underscores our dedication to fostering entrepreneurship and helping innovative businesses scale and thrive internationally.”